Quantcast
Last updated on April 23, 2014 at 1:22 EDT

Latest Discgenics Inc. Stories

2013-04-03 12:29:21

SALT LAKE CITY, April 3, 2013 /PRNewswire/ -- DiscGenics, Inc. announces that Kevin T. Foley, MD will present at the upcoming Lumbar Spine Research Society (LSRS) Annual Meeting on April 12, 2013 in Chicago. The lecture, entitled "Initial In Vivo Efficacy of a Novel, Injectable Cellular Therapy for Degenerative Disc Disease," will feature data supporting the safety and efficacy of a new therapy under development called Injectable Discogenic Cell Therapy (IDCT) in an animal model of...

2013-02-28 12:27:19

SALT LAKE CITY, Feb. 28, 2013 /PRNewswire/ -- Discgenics announces the successful completion of an animal study demonstrating safety and efficacy of its novel therapy for reducing back pain caused by degenerative disc disease. This product, known as Injectable Discosphere Cell Therapy (IDCT), features Discgenics' patented, allogeneic, human disc-derived stem cell technology. The study showed that after one injection of IDCT in degenerated discs there was a restoration of disc height...

2012-07-25 06:25:03

SALT LAKE CITY, July 25, 2012 /PRNewswire/ -- Discgenics, Inc. (Discgenics) announced today the receipt of a "Notice of Issuance" from the United States Patent and Trademark Office (USPTO) on it first patent, "Compositions of Adult Disc Stem Cells and Methods for the Treatment of Degenerative Disc Disease". Discgenics' CEO, Flagg Flanagan said, "We are excited to have obtained our first patent that provides Discgenics with coverage on our proprietary culture system that includes a...

2012-06-28 06:27:16

SALT LAKE CITY, June 28, 2012 /PRNewswire/ -- Discgenics, Inc. (Discgenics) announces the completion of its Memphis, TN research-feasibility activities and the establishment of its development phase operations and activities in Salt Lake City, UT. Discgenics was founded in Memphis, TN during late 2007. The core to Discgenics' technology is a proprietary patented culture system that uses human nucleus pulposus (NP) tissue as a source for adult disc stem cells that can be expanded...

2012-06-26 06:25:02

SALT LAKE CITY, June 26, 2012 /PRNewswire/ -- Discgenics, Inc. (Discgenics), a spinal therapeutics company that is developing a proprietary disc stem cell technology to treat degenerative disc disease, announces the appointment of Robert M. Wynalek as its Chief Operating and Commercialization Officer. Discgenics' CEO Flagg Flanagan said, "we are truly excited to have Bob join us in an executive capacity in addition to his role as a Discgenics board director and investor. Bob brings to...